# EDGAR Filing Document

**Accession Number:** 0001553846
**File Stem:** 0001178913-23-001071
**Filing Date:** 2023-3
**Character Count:** 22208
**Document Hash:** 4320cfb435ef2c09a0a3bba166e45910
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-23-001071.hdr.sgml**: 20230321

**ACCESSION NUMBER**: 0001178913-23-001071

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230321

**FILED AS OF DATE**: 20230321

**DATE AS OF CHANGE**: 20230321

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RedHill Biopharma Ltd.
- **CENTRAL INDEX KEY:** 0001553846
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35773
- **FILM NUMBER:** 23747813

**BUSINESS ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739
- **BUSINESS PHONE:** 972-3-541-3131

**MAIL ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739

------

 **UNITED STATES** 

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 6-K

#### Report of Foreign Private Issuer

#### Pursuant to Rule 13a-16 or 15d-16

#### of the Securities Exchange Act of 1934
For the month of March 2023<br> Commission File No.:001-35773

### REDHILL BIOPHARMA LTD.
(Translation of registrant's name into English)

#### 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Attached hereto and incorporated by reference herein is a press release issued by the Registrant entitled: "*RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders*"*.*

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099) and on June 27, 2022 (File No. 333-265845), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848) and on July 29, 2021 (File No. 333-258259).

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | REDHILL BIOPHARMA LTD. |
|  | (the "Registrant") |
| Date: March 21, 2023 | By: <u>/s/ Dror Ben-Asher</u> |
|  | Dror Ben-Asher  |
|  | Chief Executive Officer |

---

------

![](image00001.jpg)<br>

Press Release<br>

### RedHill Initiates First Community-Setting Warranty Program

### to Refund Talicia Non-Responders
*RedHill commits to reimburse out-of-pocket costs for Talicia patients that complete the full 14-day* 

*treatment course and whose infection is not eradicated based on post-treatment confirmation* 

*testing - warranty commitment extends to all commercially insured or non-insured Talicia patients<sup>1</sup>*

*--*

*Talicia warranty program believed to be the first of its kind offered for a widespread community* 

*(non-hospital) treated condition, lowering the bar for patient access to an H. pylori therapy with* 

*a demonstrated more than 90% cure rate in the confirmed adherent population*

--

*Talicia, the leading prescribed branded H. pylori therapy by U.S. gastroenterologists<sup>2</sup>, is an* 

*empiric first-line therapy for eradication of H. pylori, a bacterial infection that affects* 

*approximately 35% of the U.S. adult population<sup>3</sup>*

**RALEIGH, N.C. and TEL-AVIV, Israel, March 21, 2023,** <u>RedHill Biopharma Ltd.</u> (Nasdaq: <u>RDHL</u>) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the availability of a warranty program for its *Helicobacter pylori* (*H. pylori*) eradication therapy, Talicia<sup>®</sup><sup>4</sup>, in which RedHill commits to reimburse patient out of pocket costs should Talicia not work. Talicia is the most prescribed branded agent by gastroenterologists<sup>2</sup> and this warranty commitment extends to all commercially insured and non-insured Talicia patients who complete the full 14-day treatment course and whose infection is not eradicated based on post-treatment confirmation testing.

**Dr. June Almenoff, MD, Ph.D., RedHill's Chief Medical Officer said: "***H. pylori* is the number one risk factor for gastric cancer and a major risk factor for development of peptic ulcers, including bleeding ulcers which could require hospitalization<sup>5</sup><sup>,</sup><sup>6</sup>. In a pivotal clinical trial, Talicia demonstrated a more than 90% cure rate in patients in the confirmed adherent population and 84% in the intent-to-treat population, with a less than 1% discontinuation rate. Our clinical trial data support a high degree of confidence in both the efficacy and tolerability of Talicia<sup>4,</sup> <sup>7</sup>. We are committed to working towards all appropriate patients having access to this important medication and, to our knowledge, this is the first time a warranty program has been offered for a widespread community (non-hospital) treated condition and should serve to lower the bar for patient access."

------

Clarithromycin-based triple therapy continues to wane in effectiveness. A 2021 study demonstrated only 68.5% eradication with traditional clarithromycin-based triple therapy, which declined further to 32% in patients harboring resistant *H. pylori* organisms<sup>8</sup>. Other studies have also shown that for clarithromycin-resistant strains of *H. pylori* the risk of eradication failure increases 3-7–fold when treated with clarithromycin-containing regimens<sup>9</sup><sup>,</sup><sup>10</sup>. Clarithromycin-based treatment efficacy can also be negatively impacted by patient BMI or diabetic status, neither of which impact Talicia's eradication rates<sup>11</sup><sup>,</sup><sup>12</sup>.

In 2017 the American College of Gastroenterology guidelines were changed to recommend against using clarithromycin in the majority of situations<sup>8</sup>, in particular where there is known resistance or increased risk for resistance, including any previous *H. pylori* treatment or treatment for any reason with a macrolide antibiotic (e.g. erythromycin, clarithromycin, azithromycin), which accounts for approximately 100 million Americans every four years<sup>13</sup>.

**About *H. pylori* infection**<br> *H. pylori* is a bacterial infection that affects approximately 35%<sup>3</sup> of the U.S. population, with an estimated two million patients treated annually<sup>14</sup>. Worldwide, more than 50% of the population has<br> *H. pylori* infection, which is classified by the WHO as a Group 1 carcinogen. It remains the strongest known risk factor for gastric cancer<sup>15</sup> and a major risk factor for peptic ulcer disease<sup>16</sup> and gastric mucosa-associated lymphoid tissue (MALT) lymphoma<sup>17</sup>. More than 27,000 Americans are diagnosed with gastric cancer annually<sup>18</sup>. Eradication of *H. pylori* is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain *H. pylori*-positive due to high resistance of *H. pylori* to antibiotics – especially clarithromycin – which is still commonly used in standard combination therapies<sup>5</sup>.

**About Talicia**<br> Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of *H. pylori* infection in adults.

Talicia is the only low-dose rifabutin-based therapy approved for the treatment of *H. pylori* infection and is designed to address *H. pylori's* high resistance to other antibiotics. The high rates of *H. pylori* resistance to clarithromycin have led to significant rates of treatment failure with clarithromycin-based therapies and are a strong public health concern, as highlighted by the ACG, FDA and the World Health Organization (WHO) in recent years.

------

In the pivotal Phase 3 study, Talicia demonstrated 84% eradication of *H. pylori* infection in the intent-to-treat (ITT) group vs. 58% in the active comparator arm (p<0.0001). Minimal to zero resistance to rifabutin, a key component of Talicia, was detected in RedHill's pivotal Phase 3 study. Further, in an analysis of data from this study, it was observed that subjects who were confirmed adherent<sup>19</sup> to their therapy had response rates of 90.3% in the Talicia arm vs. 64.7% in the active comparator arm<sup>20</sup>. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. <br>Talicia is eligible for a total of eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents which extend patent protection until 2034 with additional patents and applications pending and granted in various territories worldwide.

#### TALICIA: IMPORTANT SAFETY INFORMATION
**Tell your healthcare provider about all of the medicines you take**, including prescription or non-prescription medications or herbal supplements before starting Talicia. Talicia may affect the way other medicines work, and other medicines may affect the way Talicia works. Do not start any new medications while taking Talicia without first speaking with your healthcare provider.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• You should not take Talicia if you are known to be sensitive to any of the components of Talicia (omeprazole, amoxicillin, rifabutin), penicillins, proton pump inhibitors or rifamycins.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• You should not take Talicia if you are taking rilpivirine-containing products, delavirdine or voriconazole.

#### Before you take Talicia, tell your healthcare provider about all of your medical conditions, including if you:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Are pregnant or plan to become pregnant. Talicia may harm your unborn baby. Tell your healthcare provider if you become pregnant or think you may be pregnant during your treatment with Talicia.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Have severe kidney disease or liver disease.

#### When taking Talicia, do not crush or chew capsules. Do not take Talicia with alcohol.
**Call your healthcare provider immediately if while taking Talicia you develop**:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• New rash or other skin changes, muscle or joint pains, swelling of any area of the body, severe flu-like symptoms, difficulty breathing, fever, blood in your urine, increased or decreased urination, drowsiness, confusion, nausea,
 vomiting, ongoing stomach pain, bloody diarrhea, or if diarrhea continues after therapy is completed, weight gain or changes in your eyesight.

------

#### What are the common side effects of Talicia?
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The most common side effects of Talicia are diarrhea, headache, nausea, stomach pain, rash, indigestion, mouth or throat pain, vomiting, and vaginal yeast infection. Call your healthcare professional for medical advice about side
 effects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Tell your healthcare provider if you experience tiredness, weakness, achiness, headaches, dizziness, depression, increased sensitivity to light, or pain when taking a deep breath.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Talicia may reduce the effectiveness of oral or other forms of hormonal birth-control. You should use an additional non-hormonal highly effective method of birth control while taking Talicia.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• You may experience a brown-orange discoloration of your urine or tears while taking Talicia.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The information here is not comprehensive. Talk to your healthcare provider to learn more.

#### APPROVED USE FOR TALICIA
TALICIA is a prescription medicine for the treatment of a bacteria, *Helicobacter pylori (H. pylori)*, in the stomach of adults.

**<u>Click here for the full Prescribing Information</u>** for TALICIA.

You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at 1-833-ADRHILL (1-833-237-4455) or the FDA at 1-800-FDA-1088 or <u>www.fda.gov/medwatch.</u>

#### About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: <u>RDHL</u>) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, **Talicia**<sup>®</sup> for the treatment of *Helicobacter pylori (H. pylori)* infection in adults<sup>4</sup>, and **Aemcolo**<sup>®</sup> for the treatment of travelers' diarrhea in adults<sup>21</sup>. RedHill's key clinical late-stage development programs include: (i) **RHB-204**, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) **opaganib (ABC294640)**, a first**-**in**-**class oral broad-acting, host-directed, SK2 selective inhibitor targeting multiple indications, including for pandemic preparedness, with a Phase 2/3 program for hospitalized COVID-19 and a Phase 2 program in oncology and a radiation protection program ongoing; (iii) **RHB-107** (**upamostat**), an oral broad-acting, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) **RHB-104**, with positive results from a first Phase 3 study for Crohn's disease; and (v) **RHB-102**, with expected UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D. More information about the Company is available at <u>www.redhillbio.com</u>/ <u>twitter.com/RedHillBio</u>.

------

*This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties, including without limitation the risk that the Company will not succeed to expand Talicia's reach to additional ex-U.S. territories; as well as other risk and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia<sup>®</sup>; (v) the Company's ability to successfully commercialize and promote Talicia<sup>®</sup> and Aemcolo<sup>®</sup>; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; and (xiv) competition from other companies and technologies within the Company's industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on March 17, 2022. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.*

**Company contact:**<br> Adi Frish<br> Chief Corporate & Business Development Officer<br> RedHill Biopharma<br> +972-54-6543-112<br> <u>adi@redhillbio.com</u><br>

Category: Commercial

------

<sup>1</sup> Talicia Warranty Program eligibility: <u>https://www.talicia.com/wp-content/uploads/2022/05/RHTC697-Cash-Pay-Warranty-Program-Leave-Behind.pdf</u>

<sup>2</sup> IQVIA XPO Data on file

<sup>3</sup> Hooi JKY et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420-429.

<sup>4</sup> Talicia<sup>®</sup> (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of *H. pylori* infection in adults. For full prescribing information see: <u>www.Talicia.com</u>.

<sup>5</sup> Malfertheiner, P., et al., Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut, 2017. 66(1): p. 6-30.

<sup>6</sup> Wroblewski, L.E., R.M. Peek, Jr., and K.T. Wilson, Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev, 2010. 23(4): p. 713-39.

<sup>7</sup> Kalfus, I.N., et al., Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial. Antibiotics (Basel), 2020. 9(10).

<sup>8</sup> Chey, W.D., et al., Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology, 2022. 163(3): p. 608-619.

<sup>9</sup> Savoldi, A., et al., Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology, 2018. 155(5): p. 1372-1382 e17.

<sup>10</sup> Park, J.Y., et al., Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. Dig Dis Sci, 2016. 61(8): p. 2373-2380.

<sup>11</sup> Diabetes Data on File

<sup>12</sup> Kao, J.Y., Helicobacter pylori eradication by low-dose rifabutin triple therapy (RHB-105) is unaffected by high body mass index. GastroHep, 2021. 3(7): p. 426-434.

<sup>13</sup> Olesen, S.W., D. MacFadden, and Y.H. Grad, Cumulative Probability of Receiving an Antibiotic Prescription over Time. N Engl J Med, 2019. 380(19): p. 1872-1873.

<sup>14</sup> IQVIA Custom Study for RedHill Biopharma, 2019

<sup>15</sup> Lamb A et al. Role of the *Helicobacter pylori*-Induced inflammatory response in the development of gastric cancer. J Cell Biochem 2013;114.3:491-497.

<sup>16</sup> NIH – *Helicobacter pylori* and Cancer, September 2013.

<sup>17</sup> Hu Q et al. Gastric mucosa-associated lymphoid tissue lymphoma and *Helicobacter pylori* infection: a review of current diagnosis and management. Biomarker research 2016;4.1:15.

<sup>18</sup> National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER).

<sup>19</sup> Defined as the PK population which included those subjects in the ITT population who had demonstrated presence of any component of investigational drug at visit 3 (approx. day 13) or had undetected levels drawn >250 hours after the last dose.

<sup>20</sup> The pivotal Phase 3 study with Talicia<sup>®</sup> demonstrated 84% eradication of *H. pylori* infection with Talicia<sup>®</sup> vs. 58% in the active comparator arm (ITT analysis, p<0.0001).

<sup>21</sup> Aemcolo<sup>®</sup> (rifamycin) is indicated for the treatment of travelers' diarrhea caused by noninvasive strains of *Escherichia coli* in adults. For full prescribing information see: <u>www.aemcolo.com</u><u>.</u>

------